ICT-121 / EOM Pharma - LARVOL DELTA

Immunological targeting of CD133 in recurrent glioblastoma: A multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy. (ASCO 2017) - P1; "The results from this Phase I trial suggest that ICT-121 is both safe and well-tolerated with an immune response seen in a subset of patients."

Clinical • P1 data • Biosimilar • Oncology

ImmunoCellular Therapeutics announces asset purchase agreement with private biotechnology company (PRNewswire) - "ImmunoCellular Therapeutics...announced an agreement with a privately held biotechnology company (the "Purchaser") for the purchase of substantially all of ImmunoCellular's remaining clinical and pre-clinical assets, including its preclinical and clinical programs, technology, intellectual property and know-how. ImmunoCellular's therapeutic assets are comprised of ICT-107 (phase 3-ready for glioblastoma), ICT-121 (phase 1 completed for recurrent glioblastoma) and ICT-140 (phase 1/2-ready for ovarian cancer), each of which is a patient-specific dendritic cell-based immunotherapy targeting solid tumors."

Licensing / partnership